Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.

CONCLUSIONS: This study represents the first comprehensive cohort analysis of nivolumab or pembrolizumab-associated hypophysitis in a large patient group. Hypophysitis occurs rarely with these medications, and these patients have a distinct phenotype compared to hypophysitis after treatment with ipilimumab or ipilimumab plus nivolumab.
PMID: 31176301 [PubMed - as supplied by publisher]

Source: European Journal of Endocrinology - May 31, 2019 Category: Endocrinology Authors: Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen J, Sullivan R, Nachtigall LB, Tritos N Tags: Eur J Endocrinol Source Type: research